Titration of carvedilol in elderly heart failure patients

被引:6
作者
Lawless, CE
Tamlyn, T
Shah, R
Karim, FM
Khan, E
Creech, S
机构
[1] DuPage Med Grp Cardiol, Winfield, IL 60190 USA
[2] Loyola Univ, Med Ctr, Dept Cardiol, Heart Failure Program & Serv, Maywood, IL 60153 USA
[3] Statistically Significant Consulting LLC, Addison, IL USA
关键词
D O I
10.1111/j.1076-7460.2005.04525.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Physicians may withhold beta blockers from elderly heart failure patients based on perceptions of poor tolerability in this group. This study analyzed the success and tolerability of carvedilol titration in elderly (70 years and older) and younger (younger than 70) heart failure patients (n =360). The mean duration of titration was similar in both groups. The target carvedilol dosage (50 mg/d) was achieved by 55.3% and 62.0%, and a partial dose was achieved by 44.7% and 35.5% (p =0.028) of elderly and younger patients, respectively. The mean achieved dosage was lower in elderly patients than in younger patients (42.4 +/- 27.2 mg/d vs. 55.1 +/- 30.1 mg/d; p < 0.0001), possibly due to significant between-group differences in baseline characteristics or rates of target dose achieved. When adjusted for body weight, the mean achieved dose was similar in elderly (0.58 +/- 0.32 mg/kg/d) and younger (0.64 +/- 0.30 mg/kg/d) patients (p =nonsignificant). Adverse events were more frequent in the elderly but did not appear to significantly impact titration duration or carvedilol dose achieved when corrected for body weight. In conclusion, carvedilol should not be withheld from elderly heart failure patients based on perceptions of poor potential tolerability.
引用
收藏
页码:230 / 235
页数:6
相关论文
共 21 条
[1]  
Adams KF, 1999, J CARD FAIL, V5, P357
[2]  
*AM HEART ASS, 2005, HEART DIS STROK 2005
[3]  
[Anonymous], 2000, AM J MANAG CARE, V6, pS299
[4]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[5]   Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure [J].
Colucci, WS ;
Packer, M ;
Bristow, MR ;
Gilbert, EM ;
Cohn, JN ;
Fowler, MB ;
Krueger, SK ;
Hershberger, R ;
Uretsky, BF ;
Bowers, JA ;
SacknerBernstein, JD ;
Young, ST ;
Holcslaw, TL ;
Lukas, MA .
CIRCULATION, 1996, 94 (11) :2800-2806
[6]   Incidence and aetiology of heart failure - A population-based study [J].
Cowie, MR ;
Wood, DA ;
Coats, AJS ;
Thompson, SG ;
Poole-Wilson, PA ;
Suresh, V ;
Sutton, GC .
EUROPEAN HEART JOURNAL, 1999, 20 (06) :421-428
[7]  
FOWLER MB, 1997, J AM COLL CARDIOL, pA285
[8]  
FRANCIOSA JA, 2004, AM HEART ASS ANN M N
[9]   Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure - Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial [J].
Gattis, WA ;
O'Connor, CM ;
Gallup, DS ;
Hasselblad, V ;
Gheorghiade, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (09) :1534-1541
[10]   Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials [J].
Heidenreich, PA ;
Lee, TT ;
Massie, BM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (01) :27-34